Next-generation Sequencing (NGS) Market worth $27.0 billion by 2027 | Illumina (US), Thermo Fisher Scientific (US), PerkinElmer (US), BGI Group (China), Agilent Technologies (US), Eurofins Scientific (Luxembourg), Pacific Biosciences (US)

Next-generation Sequencing (NGS) Market is projected to reach USD 27.0 billion by 2027 from USD 13.0 billion in 2022, at a CAGR of 15.7% during the forecast period of 2022 to 2027 according to a new report by MarketsandMarkets™. The next-generation sequencing market is expected to grow at a CAGR of 15.7% during the forecast period. The growth of the market is attributed to launch of technologically advanced NGS systems and improving regulatory and reimbursement scenarios for NGS-based diagnostic tests. However, the end-user budget constraints in developing countries are expected to restraint the growth of the market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=546&utm_source=OPenpr&utm_campaign=paid&utm_content=referral

Browse in-depth TOC on "Next-generation Sequencing (NGS) Market"

517 - Tables
48 - Figures
477 - Pages

Consumables segment accounted for the largest share of next-generation sequencing market

Next-generation sequencing market by product & service is categorized into presequencing products & services, NGS platforms, NGS consumables, services for NGS platforms, sequencing services, and bioinformatics. NGS consumables dominated the market in 2021. The large share of this segment can be attributed to launch of new NGS consumables and demand for reagents and kits.

Sequencing by synthesis segment accounted for the largest share of next-generation sequencing market

Based on technology, the next-generation sequencing market is segmented into sequencing by synthesis, ion semiconductor sequencing, nanopore sequencing, single-molecule real-time sequencing, and other sequencing technologies. Sequencing by synthesis segment dominated the market in 2021. The growth of this segment is attributed to launch of new NGS platforms based on sequencing by synthesis technology.

Diagnostics segment accounted for the largest share of next-generation sequencing market

Based on application, the next-generation sequencing market is categorized into diagnostics, drug discovery & development, agricultural & animal research, and other applications. The diagnostics segment is further categorized into cancer diagnostics, infectious disease diagnostics, reproductive health diagnostics, and other diagnostic applications. The drug discovery & diagnostics segment is further categorized into pharmacogenomics, and other discovery & diagnostics applications. The diagnostics application segment dominated the market in 2021. The growth of this segment is attributed to the increasing demand for NGS based diagnostic products for cancer and noninvasive prenatal testing (NIPT).

The academic institutes & research center segment is the fastest-growing end user segment of the next-generation sequencing market

Based on end users, the next-generation sequencing market is segmented into academic institutes & research centers, hospitals & clinics, pharmaceutical & biotechnology companies, and other end users. The academic institutes & research centers segment held largest market share in 2021. The largest share of the segment us attributed to growing number of collaborations between NGS market players and academic & research institutes.

North America accounted for the largest share of the next-generation sequencing market

By region, the next-generation sequencing market is segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East and Africa (MEA). North America accounted for the largest share of the NGS market in 2021. Some of the factors driving the growth of the market are increasing demand for new NGS based diagnostic tools, availability of research funding, and presence of prominent market players.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=546&utm_source=OPenpr&utm_campaign=paid&utm_content=referral

Next-generation Sequencing (NGS) Market Dynamics:

Drivers:

Advancements in NGS platforms
iSeq 100 System
Ion GeneStudio S5
Declining costs of genome sequencing
Improving regulatory and reimbursement scenario for NGS-based diagnostic tests
Growing incidence of cancer and increasing applications of next-generation sequencing in cancer research

Restraints:

End-user budget constraints in developing countries

Opportunities:

Government & private support for large-scale sequencing
Application of NGS in precision medicine and molecular diagnostics
NGS data analysis using big data

Challenges:

Interpretation of complex data from NGS platforms
Ethical issues
Introduction of alternative technologies
Industry Trends:

Development of portable sequencing technologies
Partnerships & collaborations for technological advancements in NGS

Key Market Players:

The prominent players in next-generation sequencing (NGS) market are Illumina (US), Thermo Fisher Scientific (US), PerkinElmer (US), BGI Group (China), Agilent Technologies (US), Eurofins Scientific (Luxembourg), Pacific Biosciences (US), Oxford Nanopore Technologies (UK), QIAGEN (Netherlands), F. Hoffmann-La Roche AG (Switzerland), Brooks Automation (US), Psomagen, Inc. (US), 10x Genomics (US), Tecan Group (Switzerland), Zymo Research (US), Takara Bio (Japan), Promega Corporation (US), CD Genomics (US), New England Biolabs (US), and Novogene Corporation (China).

Recent Developments:

In October 2022, Illumina (US) and GenoScreen (France) partnered to expand access to genomic testing for multidrug-resistant tuberculosis in countries most impacted by tuberculosis.

In October 2022, Illumina (US) entered a strategic research collaboration with AstraZeneca (UK) to improve the efficiency of pharma pipelines by leveraging the ability to identify genetic variants that contribute to human diseases.

In September 2022, Thermo Fisher Scientific (US) received FDA approval for the Oncomine Dx Target Test as the first NGS-based companion diagnostic to aid in therapy selection for patients with RET Mutations/Fusions in thyroid cancers.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=546&utm_source=OPenpr&utm_campaign=paid&utm_content=referral

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/next-generation-sequencing-ngs-technologies-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/ngs-technologies.asp

About MarketsandMarkets™:

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

This release was published on openPR.